|
|
|
eMedicine Journal
>
Emergency Medicine
>
Environmental
Burns, Thermal Synonyms, Key Words, and Related Terms: thermal injury, scalds, burn injury, contact burns, firework burns, fire deaths, thermal burns |
||||||||||
|
Author Information | Introduction | Clinical | Differentials | Workup | Treatment | Medication | Follow-up | Miscellaneous | Test Questions | Pictures | Bibliography
|
| AUTHOR INFORMATION | Section 1 of 12 |
Authored by Jerome FX Naradzay, MD, FACEP, Emergency Services Medical Director, Department of Emergency Medicine, Maria Parham Medical Center
Coauthored by Roy Alson, MD, PhD, FACEP, FAAEM, Associate Medical Director, North Carolina Baptist AirCare; Associate Professor, Department of Emergency Medicine, Wake Forest University School of Medicine
Jerome FX Naradzay, MD, FACEP, is a member of the following medical societies: American College of Emergency Physicians, and Society for Academic Emergency Medicine
Edited by Debra Slapper, MD, Consulting Staff, Department of Emergency Medicine, St Anthony's Hospital; Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine; Jon Mark Hirshon, MD, MPH, Associate Professor, Department of Emergency Medicine, University of Maryland School of Medicine; John Halamka, MD, Chief Information Officer, CareGroup Healthcare System, Assistant Professor of Medicine, Department of Emergency Medicine, Beth Israel Deaconess Medical Center; Assistant Professor of Medicine, Harvard Medical School; and Jonathan Adler, MD, Attending Physician, Department of Emergency Medicine, Massachusetts General Hospital; Division of Emergency Medicine, Harvard Medical School
| Author's Email: | Jerome FX Naradzay, MD, FACEP | |
|---|---|---|
| Editor's Email: | Debra Slapper, MD |
eMedicine Journal, November 15 2006, VOLUME 7,
Number 11
| INTRODUCTION | Section 2 of 12 |
Background: Burn injuries account for an estimated 700,000 annual emergency department (ED) visits per year. Of these, 45,000 require hospitalizations. Approximately half of these patients are hospitalized at one of the 125 specialized burn treatment centers.
Most burns are not life threatening, but each burn causes a significant amount of pain for the patient, and some degree of psychological trauma to all those involved. From the patient's perspective, even superficial burns carry a risk of scar formation. At temperatures greater than 120°F, it only takes 3 seconds to burn a child’s skin severely enough to require surgery. Rapid evaluation by the emergency physician (EP) is essential to address pain management, mitigate the psychological impact of the burn, and identify intentional burns. Following initial intervention, providing appropriate follow-up, even for the most minor burns, is imperative.
To effectively evaluate, treat, and, ultimately, prevent burns, understanding the different methods of categorizing burns is helpful. The general categories include life-threatening versus non–life-threatening, accidental versus intentional, recreational versus occupational, and domestic (home or residence) versus industrial.
Identifying the type of burn is essential because unique interventions are required. Type of burns are as follows: thermal burns, chemical burns, and radiation burns. Thermal burns can be further classified according to skin depth and percentage of total body area burned. Additional descriptions for thermal burns include contact, flame, heat, and scalding.
Because emergency intervention, specialist referral, and prognosis must be considered during the EP’s evaluation, including an accurate description of the burn location, such as ophthalmic, hand, face, inhalation, soles, or perineum, is essential. The topic of this article is thermal burns; however, remember that burns can be caused by chemical agents, ionizing radiation, electromagnetic radiation, and electric current.
Pathophysiology: The skin is the largest organ of the body. While not very active metabolically, the skin serves multiple functions essential to the survival of the organism, including the following:
Major burns compromise these functions.
The skin is divided into 3 layers, as follows:
Frequency:
According to 2003 data from the US Fire Administration (USFA, an entity of the Department of Homeland Security and the Federal Emergency Management Agency [FEMA]), between 1994 and 2003, an average of 4,060 Americans lost their lives, and another 22,650 were injured annually as the result of fire. Not included in this data are the deaths attributed to fire caused by the terrorist events of September 11, 2001. In 2003, the United States had one of the highest fire death rates reported in the industrialized world at 13.5 deaths per million population. A slight increase from 12.9 deaths per million population reported in 2001 (USFA, 2003).
Slightly different findings were released by the World Fire Statistics in 2002. They reported that the fire-related death rate in the United States was 1.86 deaths per 100,000 (18.6 per million) in the year 2000. For comparison, fire-related death rates per 100,000 were higher in Finland and Hungary at 2.02 and 2.88, respectively.
States with the higher death rates in 2001 were in Arkansas (37 per million), Mississippi (30 per million), and Delaware (30 per million). The states with the lowest rates were Colorado (5.4 per million), Hawaii (4.1 per million), and Utah (3.1 per million) (USFA, 2003).
According to the USFA in 2003, 3,925 civilians lost their lives as the result of fire, 18,125 civilian injuries occurred as the result of fire, and 111 firefighters were killed in duty-related incidents.
In 2000, the World Fire Statistics Centre released fire-related death data by country (from lowest to highest number of deaths per 100,000 person) from 1995-1997 (World Fire Statistics Centre, 2000).
In the United Kingdom, more than 47 fire-related injuries occur every day.
In Greece, the estimated annual incidence of childhood firework injuries treated in EDs is 7 injuries per 100,000 children per year. Seventy percent of injuries occur in children aged 10-14 years. Boys sustain self-inflicted accidental injuries; girls are injured as bystanders. A sharp peak of firework injuries occurs in the spring when the Greek Orthodox Easter is celebrated.
Interesting data from Northern Ireland allows a comparison of burn incidence before and after the enactment of firework legislation. In the prelegislation series, the mean number of patients admitted annually was 0.38 per 100,000, while in the postlegislation series, the mean was 0.43 per 100,000. The authors concluded that legislation did not significantly affect the incidence of burns. Also in Northern Ireland, blast injuries to the hand account for more than 50% of injuries in this series.
In Bergen, Norway, the incidence of burns was 17 cases per 10,000 inhabitants. Fewer than 10% occur in individuals older than 60 years. More than a third occur in children younger than 15 years. Burns were more common in males than in females, and the burns were likely to be flame and firework burns. Interestingly, females were more likely to experience scald burns.
Mortality/Morbidity: The number of deaths from fires and burns has declined since the 1960s for several reasons. Improved burn care (ie, quality burn centers, recognition, and effective management of burn shock) has reduced the number of deaths in the early postburn period. Improved wound management and antibiotics have decreased deaths from burn wound infection.
The greatest factor in the reduction of burn-related deaths is the use of smoke detectors. In the United States, most people killed in house fires die from smoke inhalation rather than from burns (see Smoke Inhalation and Toxicity, Carbon Monoxide).
Race:
Age: Minor burns are more common in younger adults, often as a result of cooking or occupational exposures. Teenaged males are at increased risk of injury from fireworks; scald injuries are more common in young children. Most scald injuries in young children result from improper setting of domestic hot water heaters and spillage of cooking pots or beverages. Both types of injuries are easily prevented.
| CLINICAL | Section 3 of 12 |
History: The EP must consider the type of burn (thermal, chemical, radiation) and the location during early burn management. Once it has been determined that the burn is a thermal burn, the EP must add to the description: contact (with source name), scald (with fluid or gas type), heat, and flame. Systemic injury, duration, intentional versus accidental, and location of the burn must all be considered during the critical early burn period.
Other important points for the EP to determine include the patient's tetanus immunization status as well as the components of the history outlined by the mnemonic AMPLE, as follows:
History should also include the following:
Physical: Thermal, chemical, and radiation constitute the large classes of burn types. Each can be further broken down, with each subsection directing the EP to provide more specific treatment.
The most common type of burns are thermal burns. Soft tissue is burned when it is exposed to temperatures above 115º F (46°C). The extent of damage depends on surface temperature and contact duration. A thermal burn causes coagulation of soft tissue. As soft tissue temperature increases, capillary permeability increases, fluid loss occurs, and plasma viscosity increases with resultant microthrombi formation. Fluid loss can lead to hypovolemia and shock, depending on the amount of loss and response to resuscitation.
Burns cause an increased metabolic rate and energy metabolism. How the individual responds to the increased energy demands will dictate recovery.
Causes:
| DIFFERENTIALS | Section 4 of 12 |
Burns, Chemical
Burns, Ocular
Electrical Injuries
Hydrofluoric Acid Burns
Smoke Inhalation
Sunburn
| WORKUP | Section 5 of 12 |
Lab Studies:
Imaging Studies:
Other Tests:
| TREATMENT | Section 6 of 12 |
Prehospital Care:
Emergency Department Care:
Consultations:
| MEDICATION | Section 7 of 12 |
Pain management and topical medication application are two therapeutic interventions for burns.
Of the two, rapid and effective pain reduction is central to burn patient care. The EP must recognize that for the patient in pain every minute without treatment is another minute with pain. Treat the patient's pain quickly and effectively.
With few exceptions, the EP should not hesitate to insert an IV line, preferably in a nonburned area, and provide IV analgesic.
IV administration is ideal for the acute treatment of patients who require immediate pain relief. The pain level can be reduced or aborted almost immediately, and additional medication can be provided quickly. The IV line can be used for fluid therapy, adjunctive medications, and blood sample collection.
The time for oral pain medication to take effect is too long for the patient who is suffering from a fresh burn. Oral medication is more suitable for patients who will be discharged to home.
The EP should resist the propensity of emergency staff to apply topical burn ointment as the first intervention. Except for EMLA cream or lidocaine ointment, topical thermal burn ointments and gels address microbial growth on the burned tissue; they do not address the pain, per se.
If the patient has a burn that requires the patient to be transferred to a burn center, it may be better not to apply any ointment at all. Treatment should be limited to removing the source of the thermal burn, debriding contaminated tissue, and covering the burned area with a nonadhesive cover (petroleum-based gauze) then a sterile, dry towel or sheet.
The emergency medical director should work with the emergency nursing director to establish thermal burn evaluation and treatment protocols including standing orders. If the nursing or triage staff can identify a thermal burn, estimate the degree, depth, and associated injuries (airway) then protocols and policies can be put into place so that the triage nurse can initiate pain intervention therapy. Regardless of the burn severity, standing orders to provide pain relief for the burned patient should be in place.
A prudent emergency medical director should collaborate with commonly used burn centers. The sending and receiving facilities should have protocols for analgesic treatment, IV access, and burn dressing. Preapproved protocols and arrangements provide a seamless transfer of care for the burned patient.
Drug Category: Analgesics -- Opiates provide rapid pain relief. Opiates can be titrated to achieve the desired comfort level for each patient. Opiates side effects can be reversed quickly.
| Drug Name | Morphine sulfate (Duramorph, Astramorph, MS Contin) -- DOC for burn pain treatment because of the reliable and predictable effects, safety profile, and ease of reversibility with naloxone. Morphine sulfate administered IV can be dosed in a number of ways and is commonly titrated until desired effect is obtained. |
|---|---|
| Adult Dose | Initial IV, IM, or SC: 0.1-0.2 mg/kg; avoid IM and SC injections in burn patients Maintenance dose: 5-20 mg/70 kg IV/IM/SC q4h (2 mg is a good starting dose in patients who may be hypovolemic) |
| Pediatric Dose | Neonates: 0.05-0.2 mg/kg/dose IV q4h Children: 0.1-0.2 mg/kg/dose IV q2-4h |
| Contraindications | Documented hypersensitivity; hypotension; potentially compromised airway in which establishing rapid airway control would be difficult |
| Interactions | Phenothiazines may antagonize analgesic effects; tricyclic antidepressants, MAOIs, and other CNS depressants may potentiate adverse effects |
| Pregnancy | C - Safety for use during pregnancy has not been established. |
| Precautions | Avoid in respiratory depression, nausea, emesis, constipation, and urinary retention; caution in atrial flutter and other supraventricular tachycardias; has vagolytic action and may increase ventricular response rate Physicians must be aware of a National Patient Safety Goal (NPSG): Do not abbreviate morphine sulfate "MS" or "MSO4" (always write clearly "morphine sulfate" to avoid confusion with other drugs); similar "forbidden" abbreviations under the NPSG guidelines include avoiding "SC" or "SQ" for subcutaneous injections (the provider must write legibly: "subcutaneously") |
| Drug Name | Meperidine (Demerol) -- Narcotic analgesic with actions similar to those of other opiates. May produce less constipation, smooth muscle spasm, and depression of cough reflex than similar analgesic doses of morphine. |
|---|---|
| Adult Dose | 25-75 mg PO/IV/IM/SC q3-4h prn |
| Pediatric Dose | 1-1.8 mg/kg (0.5-0.8 mg/lb) PO/IV/IM/SC q3-4h prn; not to exceed adult dose |
| Contraindications | Documented hypersensitivity; concurrent MAOIs; upper airway obstruction or significant respiratory depression; during labor when delivery of premature infant anticipated |
| Interactions | Cimetidine and protease inhibitors may increase toxicity; hydantoins may decrease effects |
| Pregnancy | C - Safety for use during pregnancy has not been established. |
| Precautions | Caution in patients with head injuries because meperidine may increase respiratory depression and CSF pressure (use only if absolutely necessary); caution postoperatively and with history of pulmonary disease (suppresses cough reflex); substantially increased dose levels, because of tolerance, may aggravate or cause seizures even if no prior history of convulsive disorders; monitor closely for meperidine-induced seizure activity if prior seizure history; caution in patients with a creatinine clearance <50 mL/min; avoid multiple injections in short time, particularly in patients >65 y |
| Drug Name | Hydrocodone bitartrate and acetaminophen (Vicodin ES) -- Drug combination indicated for relief of moderate to severe pain. |
|---|---|
| Adult Dose | 1-2 tab or cap PO q4-6h prn for pain |
| Pediatric Dose | <12 years: 10-15 mg/kg/dose acetaminophen PO q4-6h prn; not to exceed 2.6 g/d of acetaminophen or 5 mg of hydrocodone bitartrate/dose >12 years: 750 mg acetaminophen PO q4h; not to exceed 5 doses/d acetaminophen or 10 mg of hydrocodone bitartrate/dose |
| Contraindications | Documented hypersensitivity; elevated intracranial pressure |
| Interactions | Phenothiazines may decrease analgesic effects; CNS depressants or tricyclic antidepressants may increase toxicity |
| Pregnancy | C - Safety for use during pregnancy has not been established. |
| Precautions | Tablets contain metabisulfite, which may cause hypersensitivity; caution in patients dependent on opiates because this substitution may result in acute opiate-withdrawal symptoms; caution in severe renal or hepatic dysfunction |
| Drug Name | Hydromorphone (Dilaudid) -- A hydrogenated ketone of morphine. Hydromorphone is a narcotic analgesic. Analgesic action of parenterally administered Dilaudid is apparent within 15 min and usually remains in effect for > 5 h. |
|---|---|
| Adult Dose | 1-2 mg IV q2-4h |
| Pediatric Dose | Not recommended |
| Contraindications | Documented hypersensitivity; obstetrical analgesia; increased intracranial pressure; respiratory depression; ulcerative colitis; Crohn disease; abdominal cramping and distention |
| Interactions | Hydantoins may decrease effects; phenothiazines, CNS depressants, and tricyclic antidepressants may increase toxicity |
| Pregnancy | C - Safety for use during pregnancy has not been established. |
| Precautions | Pregnancy category D in prolonged use or high doses at term; caution in patients with head injuries because may increase respiratory depression and CSF pressure (use only if absolutely necessary); caution postoperatively and with history of pulmonary disease (suppresses cough reflex); increased dosing levels, because of tolerance, may aggravate or cause seizures (even without prior history); adjust dose in renal insufficiency (do not use in severe renal dysfunction); normeperidine metabolite accumulation may induce CNS toxicity; monitor closely for morphine-induced seizure activity if prior seizure history |
These agents will not provide rapid relief of other agents and, except for ketorolac, must be administered to patients that do not have oral intake restrictions.
| Drug Name | Ibuprofen (Ibuprin, Advil, Motrin) -- Treatment of mild pain, if no contraindications. Inhibits inflammatory reactions and pain by decreasing activity of enzyme cyclooxygenase, which results in inhibition of prostaglandin synthesis. |
|---|---|
| Adult Dose | 200-400 mg PO q4-6h while symptoms persist; not to exceed 3.2 g/d |
| Pediatric Dose | 6 months to 12 years: 20-40 mg/kg/d PO divided tid/qid >12 years: Administer as in adults |
| Contraindications | Documented hypersensitivity; peptic ulcer disease; recent GI bleeding or perforation; renal insufficiency; high risk of bleeding |
| Interactions | Aspirin increases risk of inducing serious NSAID-related adverse effects; probenecid may increase concentrations and, possibly, toxicity; may decrease effect of hydralazine, captopril, and beta-blockers; may decrease diuretic effects of furosemide and thiazides; may increase PT in patients taking anticoagulants; may increase risk of methotrexate toxicity; may increase phenytoin levels |
| Pregnancy | B - Usually safe but benefits must outweigh the risks. |
| Precautions | Category D in third trimester of pregnancy; caution in CHF, hypertension, and decreased renal or hepatic function; caution in anticoagulation abnormalities or during anticoagulant therapy (monitor PT and bleeding) |
| Drug Name | Flurbiprofen (Ansaid) -- Has analgesic, antipyretic, and anti-inflammatory effects. May inhibit cyclooxygenase, causing inhibition of prostaglandin biosynthesis that may, in turn, result in analgesic and anti-inflammatory activities. |
|---|---|
| Adult Dose | 200-300 mg/d PO divided bid/qid |
| Pediatric Dose | Not established |
| Contraindications | Documented hypersensitivity |
| Interactions | Aspirin increases risk of inducing serious NSAID-related adverse effects; probenecid may increase concentrations and, possibly, toxicity; may decrease effect of hydralazine, captopril, and beta-blockers; may decrease diuretic effects of furosemide and thiazides; may increase PT in patients taking anticoagulants; may increase risk of methotrexate toxicity; may increase phenytoin levels |
| Pregnancy | C - Safety for use during pregnancy has not been established. |
| Precautions | Category D in third trimester of pregnancy; caution in coagulation abnormalities or during anticoagulant therapy (monitor PT and bleeding); acute renal insufficiency, interstitial nephritis, hyperkalemia, hyponatremia, or renal papillary necrosis may occur; patients with preexisting renal disease or compromised renal perfusion risk acute renal failure; leukopenia occurs rarely, is transient, and usually returns to normal during therapy; persistent leukopenia, granulocytopenia, or thrombocytopenia warrants further evaluation and may require discontinuation of drug |
| Drug Name | Ketoprofen (Oruvail, Orudis, Actron) -- Used for relief of mild to moderately severe pain and inflammation. Initially administer small dosages to patients with a small body size, elderly persons, and those with renal or liver disease. Doses higher than 75 mg do not increase therapeutic effects. Administer high doses with caution and closely observe patient for response. |
|---|---|
| Adult Dose | 25-50 mg PO q6-8h prn; not to exceed 300 mg/d |
| Pediatric Dose | 3 months to 14 years: 0.1-1 mg/kg PO q6-8h >12 years: Administer as in adults |
| Contraindications | Documented hypersensitivity |
| Interactions | Aspirin increases risk of inducing serious NSAID-related adverse effects; probenecid may increase concentrations and, possibly, toxicity; may decrease effect of hydralazine, captopril, and beta-blockers; may decrease diuretic effects of furosemide and thiazides; may increase PT in patients taking anticoagulants; may increase risk of methotrexate toxicity; may increase phenytoin levels |
| Pregnancy | B - Usually safe but benefits must outweigh the risks. |
| Precautions | Category D in third trimester of pregnancy; caution in CHF, hypertension, and decreased renal or hepatic function; caution in anticoagulation abnormalities or during anticoagulant therapy (monitor PT and bleeding) |
| Drug Name | Naproxen (Anaprox, Naprelan, Naprosyn) -- Used for relief of mild to moderate pain. Inhibits inflammatory reactions and pain by decreasing activity of enzyme cyclooxygenase, which results in decrease in prostaglandin synthesis. |
|---|---|
| Adult Dose | 500 mg PO, followed by 250 mg q6-8h; not to exceed 1.25 g/d |
| Pediatric Dose | <2 years: Not established >2 years: 2.5 mg/kg/dose PO q6-8h; not to exceed 10 mg/kg/d |
| Contraindications | Documented hypersensitivity; peptic ulcer disease; recent GI bleeding or perforation; renal insufficiency |
| Interactions | Aspirin increases risk of inducing serious NSAID-related adverse effects; probenecid may increase concentrations and, possibly, toxicity; may decrease effect of hydralazine, captopril, and beta-blockers; may decrease diuretic effects of furosemide and thiazides; may increase PT in patients taking anticoagulants; may increase risk of methotrexate toxicity; may increase phenytoin levels |
| Pregnancy | B - Usually safe but benefits must outweigh the risks. |
| Precautions | Category D in third trimester of pregnancy; caution in coagulation abnormalities or during anticoagulant therapy (monitor PT and bleeding); acute renal insufficiency, interstitial nephritis, hyperkalemia, hyponatremia, and renal papillary necrosis may occur; patients with preexisting renal disease or compromised renal perfusion risk acute renal failure; leukopenia occurs rarely, is transient, and usually returns to normal during therapy; persistent leukopenia, granulocytopenia, or thrombocytopenia warrants further evaluation and may require discontinuation of drug |
| Drug Name | Ketoralac (Toradol) -- Inhibits prostaglandin synthesis by decreasing the activity of the enzyme cyclooxygenase, which results in decreased formation of prostaglandin precursors. |
|---|---|
| Adult Dose | 30 mg IV/IM q6h; not to exceed 120 mg/d 10 mg PO q4-6h; not to exceed 40 mg/d Combined duration of PO/IV/IM not to exceed 5 d |
| Pediatric Dose | Not established; recommended dose is 0.4-1 mg/kg IM once |
| Contraindications | Documented hypersensitivity; peptic ulcer disease; recent GI bleeding or perforation; renal insufficiency; high risk of bleeding; do not administer into CNS |
| Interactions | Coadministration with aspirin increases risk of inducing serious NSAID-related adverse effects; probenecid may increase concentrations and, possibly, toxicity of NSAIDs; may decrease effect of hydralazine, captopril, and beta-blockers; may decrease diuretic effects of furosemide and thiazides; may increase PT when taking anticoagulants (instruct patients to watch for signs of bleeding); may increase risk of methotrexate toxicity; phenytoin levels may be increased when administered concurrently |
| Pregnancy | B - Usually safe but benefits must outweigh the risks. |
| Precautions | Acute renal insufficiency, hyperkalemia, hyponatremia, interstitial nephritis, and renal papillary necrosis may occur; increases risk of acute renal failure in patients with preexisting renal disease or compromised renal perfusion; low WBC counts (rare) usually return to normal during ongoing therapy; discontinue therapy if leukopenia, granulocytopenia, or thrombocytopenia persists |
| Drug Name | Neomycin and polymyxin B (Neosporin) -- Used to treat minor infections. Inhibits bacterial protein synthesis and, thus, bacterial growth. Polymyxin B disrupts bacterial cytoplasmic membrane, permitting leak of intracellular constituents, causing inhibition of bacterial growth. |
|---|---|
| Adult Dose | Apply 1-4 times/d to affected areas |
| Pediatric Dose | Administer as in adults |
| Contraindications | Documented hypersensitivity |
| Interactions | None reported |
| Pregnancy | C - Safety for use during pregnancy has not been established. |
| Precautions | Extended use can lead to resistant infections and thinning or atrophy of skin |
| Drug Name | Silver sulfadiazine (Silvadene) -- Although expensive, Silvadene has antipseudomonal properties in addition to coverage for most gram-positive organisms. Avoid facial use. Useful in prevention of infections from second- or third-degree burns. Has bactericidal activity against many gram-positive and gram-negative bacteria, as well as yeast. |
|---|---|
| Adult Dose | Apply using sterile technique to affected areas bid; wash burn prior to application to remove previously applied agent |
| Pediatric Dose | >2 years: Administer as in adults |
| Contraindications | Documented hypersensitivity; neonates and infants <2 y |
| Interactions | Reduces effect of proteolytic enzymes |
| Pregnancy | C - Safety for use during pregnancy has not been established. |
| Precautions | Caution in G-6-PD deficiency and renal insufficiency |
| FOLLOW-UP | Section 8 of 12 |
Transfer:
Complications:
Prognosis:
Patient Education:
| MISCELLANEOUS | Section 9 of 12 |
Medical/Legal Pitfalls:
Special Concerns:
| TEST QUESTIONS | Section 10 of 12 |
CME Question 1: Early death from severe burn injury as a result of a house fire usually is caused by which of the following?
A: Hypovolemic shock resulting from loss of fluid from the burn wound
B: Septic shock resulting from infection of the burn wound
C: Respiratory failure from inhalation of toxic products of combustion, such as carbon monoxide
D: Associated traumatic injuries
E: None of the above
The correct answer is C: While major burns have the potential to cause loss of large fluid volumes following the destruction of the vapor barrier provided by the skin, development of clinical shock takes several hours. Most individuals who die in house fires in North America die from inhalation injuries. Aggressive management of the airway, especially in those who show signs of respiratory difficulty, who have a history of being confined in proximity to fire, or who have signs such as facial burns, can reduce the risk of death greatly.
CME Question 2: Transfer to a burn unit is indicated for which of the following patients?
A: A 5-year-old boy who fell into a campfire and acquired full-thickness burns to both legs below the knees
B: A 68-year-old man who has chronic obstructive pulmonary disease (COPD) and is well known to the ED was pulled from his fully involved trailer by the fire department (He has burns to the chest and abdomen resulting from his shirt being ignited by a cigarette and the flames fed by his home oxygen.)
C: A 27-year-old man who contacted a 220-volt power line at work (He has partial-thickness burns to his left arm and shoulder.)
D: All of the above indicate transfer to a burn unit.
E: None of the above indicate transfer to a burn unit.
The correct answer is D: On the basis of recommendations by the American Burn Association, each of these cases has one or more factors that are indicators for transfer to a burn unit. The 5-year-old boy has full-thickness burns covering over 5% total body surface area and feet. The 68-year-old man should be transferred because of his age, underlying disease, and high risk of inhalation injury. The 27-year-old man has associated electrical injury.
Pearl Question 1 (T/F): An escharotomy incision should be performed if needed in cases of thermal burns but only superficially.
The correct answer is False: Escharotomy incisions, made along the lateral aspects of the limb or in a box over the anterior chest, should go completely through the eschar (ie, through the dermis) and just into the subcutaneous fat.
Pearl Question 2 (T/F): Fluid needs for the first 24 hours for a 20-year-old woman (50 kg) with burns to the back of both legs and her back can be calculated. All of the burns are deep partial- or full-thickness burns.
The correct answer is True: Using the Rule of Nines, each leg is 18%. Half of each leg is involved: 2 X 9% = 18%. The back of the torso is 18%. Therefore, the total body surface area (TBSA) involved is 36%. Remember to include only second-degree or deeper burns in the calculation. Using the Parkland formula, the patient`s fluid requirement can be calculated as follows: 4 cm3/kg X (50 kg) X (36) = 7200 cm3 in the first 24 hours. Half of this is administered in the first 8 hours (beginning at the time of burn, not the time of arrival in the ED). Thus, the rate of fluid infusion should be 450 cm3/h for the first 8 hours, and then 225 cm3/h for the next 16 hours.
Pearl Question 3 (T/F): Fluids used in initial resuscitation of burn victims should contain colloids.
The correct answer is False: While colloid solutions have higher oncotic pressures and, thus, allow less leakage of fluids into the tissue spaces, an increased leak of protein has been shown in the early postburn period. Thus, colloids are no more effective than crystalloids in initial resuscitation of patients with burns.
Pearl Question 4 (T/F): Hot tar should be left on the skin until it cools down.
The correct answer is False: The tar should be actively cooled to terminate thermal damage. Tar can be peeled, picked, or debrided from injured skin and soft tissues once it has hardened. Polymicrobial antibiotic ointment, mineral oil, or petroleum jelly can be used to soften the tar. Organic agents, such as mayonnaise, butter, sunflower seed oil, or baby oil can be effective when removing tar. However, they must be rinsed or removed completely from occlusive sites beneath the tar that remains attached to the skin. Organic solvents, such as acetone or gasoline, can damage tissues and should be avoided.
| PICTURES | Section 11 of 12 |
| BIBLIOGRAPHY | Section 12 of 12 |
| NOTE: |
|---|
| Medicine is a constantly changing science and not all therapies are clearly established. New research changes drug and treatment therapies daily. The authors, editors, and publisher of this journal have used their best efforts to provide information that is up-to-date and accurate and is generally accepted within medical standards at the time of publication. However, as medical science is constantly changing and human error is always possible, the authors, editors, and publisher or any other party involved with the publication of this article do not warrant the information in this article is accurate or complete, nor are they responsible for omissions or errors in the article or for the results of using this information. The reader should confirm the information in this article from other sources prior to use. In particular, all drug doses, indications, and contraindications should be confirmed in the package insert. FULL DISCLAIMER |
| eMedicine Journals > Emergency Medicine > Environmental > Burns, Thermal |
| Please email us with any comments you have on our new chapter format. |
|
Author Information | Introduction | Clinical | Differentials | Workup | Treatment | Medication | Follow-up | Miscellaneous | Test Questions | Pictures | Bibliography
|
|